PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-31.05%
Cash & equivalents declining -31.05% while AGEN's grows 6.96%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-31.05%
Below half of AGEN's 6.96%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Other current assets growth < half of AGEN's 25.00%. David Dodd sees a leaner approach to short-term items.
-31.37%
≥ 1.5x AGEN's -0.10%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
76.50%
Below half AGEN's -4.02%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of AGEN's -2.17%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
≥ 1.5x AGEN's -1.11%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-21.72%
Less than half of AGEN's 8.92%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Less than half of AGEN's 13.39%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Less than half of AGEN's 6.87%. David Dodd sees far fewer liability expansions relative to competitor.
0.01%
Less than half of AGEN's 6.43%. David Dodd sees fewer share issuances vs. competitor.
-3.53%
1.25-1.5x AGEN's -3.02%. Bruce Berkowitz notes stronger reinvestment strategy.
-5.52%
Above 1.5x AGEN's -2.43%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
-33.13%
≥ 1.5x AGEN's -15.71%. David Dodd sees stronger capital base growth than competitor.
-30.47%
≥ 1.5x AGEN's -1.11%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.05%
Less than half of AGEN's -9.49%. David Dodd sees better deleveraging or stronger cash buildup than competitor.